[HTML][HTML] Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
K Rejeski, MD Jain, EL Smith - Transplantation and Cellular Therapy, 2023 - Elsevier
Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need
YS Martin, JK Franz, ME Agha, HM Lazarus - Blood Reviews, 2023 - Elsevier
Since its FDA approval, chimeric antigen receptor (CAR)-T cell therapy is changing the
landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and …
landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and …
Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma.
Interestingly, CAR T cells were no longer detectable by flow cytometry at day+ 20 after axi-
cel infusion in one of the responding patients, but we observed a new expansion of CD4+ …
cel infusion in one of the responding patients, but we observed a new expansion of CD4+ …
[HTML][HTML] 原发纵隔大B 细胞淋巴瘤的治疗进展
陈吕雯， 李建勇， 范磊 - Chinese Journal of Hematology, 2024 - ncbi.nlm.nih.gov
原发纵隔大B 细胞淋巴瘤（ PMBCL） 是一种起源于胸腺的侵袭性B 细胞淋巴瘤。
具有不同于非特指型弥漫大B 细胞淋巴瘤的临床和生物学特征， PMBCL 好发于年轻女性 …
具有不同于非特指型弥漫大B 细胞淋巴瘤的临床和生物学特征， PMBCL 好发于年轻女性 …
[PDF][PDF] Transplantation and Cellular Therapy
K Rejeski, MD Jain, EL Smith - ZUMA, 2023 - researchgate.net
Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
[PDF][PDF] Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
MD Jain, EL Smith - researchgate.net
While chimeric antigen receptor (CAR) T-cell therapy has altered the treatment landscape
for relapsed/refractory B-cell malignancies and multiple myeloma, only a minority of patients …
for relapsed/refractory B-cell malignancies and multiple myeloma, only a minority of patients …